Tech Company Financing Transactions
Goldfinch Bio Funding Round
Goldfinch Bio, based in Cambridge, raised $100 million in funding from Eventide Asset Management, Ally Bridge Group and BlackRock.
Transaction Overview
Company Name
Announced On
7/1/2020
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the Series B financing will enable the advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts -- in FSGS and DN and in CB1-mediated DN, respectively -- and will also support continued development of the Company's discovery platform and preclinical pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
215 First St. 4th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
At Goldfinch, we are pioneering a new approach to discover and develop therapeutics for kidney disease that is unprecedented.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony Johnson
Chief Financial Officer
Kyle Kuvalanka
Chief Medical Officer
Frank Czerwiec
VP - Bus. Development
Lori Rudolph-Owen
VP - Human Resources
Curtis Demick
VP - R & D
Jean-Christophe Harmange
Browse more venture capital transactions:
Prev: 7/1/2020: Aclaimant venture capital transaction
Next: 7/1/2020: Capital venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs